The role of extracorporeal membrane oxygenation (ECMO) has not been formally validated for patients with adult respiratory distress syndrome. In anticipation of publication of the conventional ventilation versus ECMO in severe adult respiratory failure (CESAR) trial, the role of ECMO in this setting was reviewed.
Since its initial description in 1967 1 , the adult respiratory distress syndrome (ARDS) has been recognised as a significant healthcare burden in Australian intensive care units 2 . Survival has improved with the adoption of proven strategies such as low tidal volume ventilation and clinicians may also consider less validated options such as prone positioning and inhaled nitric oxide 3 . However some patients develop a persistent gas exchange deficit despite maximal conventional treatment. In this scenario extracorporeal membrane oxygenation (ECMO) may be indicated. With the imminently expected publication of the conventional ventilation versus ECMO for severe adult respiratory failure (CESAR) trial, the authors felt it would be timely to review the role of this therapeutic measure in the management of patients with ARDS 4 .
THE HISTORY
The use of extracorporeal circulation had been just a theory until the isolation of heparin by McLean and Howell in 1918, thereby stopping the in-circuit coagulation that had prevented successful implementation 5, 6 . It was not until 1954 that John Gibbon invented the heart-lung machine, and described its implementation to support patients during cardiac surgery and allowing lengthy procedures to become possible for the first time 7 .
With the guidance of Walt Lillehei, DeWall worked on the first commercially viable helical reservoir oxygenator aiming to prevent the red cell damage caused by earlier designs 8 . In 1968 Kolobow and Zapol developed a membrane oxygenator and proved that long-term extracorporeal circulation was feasible without high transfusion requirements 9 . Their design was also a breakthrough in keeping the blood and gas phases independent. This was further refined by development of the hollow-fibre oxygenator which had superior gas-exchange performance over previous models 10 .
The first successful use of ECMO on an adult patient was reported by Donald Hill in 1971 11 . A 24-year-old poly-trauma patient was supported on extracorporeal oxygenation after developing "shock lung" for a total of 75 hours before successful weaning and discharge.
Currently the Extracorporeal Life Support Organisation lists on their website 42 centres in six countries having provided ECMO for an adult patient with pulmonary failure in the past five years 12 . Their database reports a total of 2115 adult respiratory patients treated worldwide with ECMO between 1990 and 2006 13 .
LOGISTICS
ECMO requires the institution of an extracorporeal circuit continuous with the patient's circulation. Blood is drained from an intravascular cannula and pumped through an oxygenator before being returned to the patient via a second cannula. The cannulae and circuit tubing are made of high-grade PVC tubing that must resist fracture. Modern oxygenators have a coiled hollow-fibre membrane which provides a large surface area to optimise gas-exchange. The circuit must be anticoagulated to prevent clot formation.
If oxygenation alone is required, then both the drainage and return cannulae are placed intravenously, namely veno-venous ECMO. In adults it is customary to place the cannulae in separate central veins. This prevents recirculation, that is, the drainage of freshly returned oxygenated blood which impairs performance.
In states of inadequate cardiac output the return cannula may be placed into the aortic arch via the internal carotid artery or into a femoral artery to provide veno-arterial ECMO.
The patient will remain on ECMO until there is satisfactory reversal of the pathology that necessitated extracorporeal life support. During the period on ECMO, as with any patient in the critical care unit, careful attention is paid to maintaining haemodynamic stability, normothermia and correction of haematological and biochemical abnormalities. The current convention is to adopt ventilator 'rest settings' as the avoidance of high pressure ventilation or high FiO 2 will enable quicker resolution of the acute lung injury 14 .
INDICATIONS
ECMO is usually indicated for adults with acute severe respiratory failure of a potentially reversible cause. Some units and trials have followed Zapol's criteria, published in 1979 15 : P a O 2 /FiO 2 ratio <50 mmHg with PEEP ≥5 cmH 2 O for more than two hours, or P a O 2 <50 mmHg with FiO 2 0.6, PEEP ≥5 cmH 2 O and shunt fraction ≥30% for more than 12 hours. Many other criteria have been subsequently developed, but it is generally accepted that ECMO be reserved for patients with refractory hypoxia and/or hypercapnia.
ECMO may be used safely in sepsis as it is not an independent prognosticator of mortality in this setting 16, 17 . There are a number of roles for ECMO in the cardiothoracic intensive care unit. It may be used as a temporary bridging measure to cardiac transplantation or before institution of a left ventricular assist device [18] [19] [20] . There has also been reported use in cardiogenic shock after surgery and for treatment of fulminant myocarditis 21, 22 . Thoracic trauma with lung contusions can lead to rapid development of acute pulmonary failure. In this setting ECMO can support the patient until adequate gas exchange and lung function return 23 . ECMO may also be used as a bridge to lung transplantation or as a supportive measure during thrombolysis or embolectomy in patients with massive pulmonary embolism 24, 25 . Controversially, ECMO has also been proposed as a rescue method for prolonged cardiopulmonary resuscitation with failure to respond to conventional measures, though the scope for this manoeuvre outside the cardiothoracic intensive care unit is limited 26 .
The National Institute of Clinical Excellence in the United Kingdom reviewed ECMO for adults and published a policy document in January 2004 27 . After scrutinising available articles, they concluded there was not sufficient evidence to support its application at that time. To this end, they recommended that ECMO should not be offered to adult patients unless they were enrolled in the CESAR trial. The sole Australian governmental policy document on ECMO was published in 1990 by the National Health Technology Advisory Panel; however this only concerned the provision of a paediatric service and made no recommendations for adult patients 28 . Similarly neither the Extracorporeal Life Support Organisation nor the National Institutes of Health in the United States have produced any formal stance on ECMO for adults.
• •

CONTRAINDICATIONS AND COMPLICATIONS
Laboratory work by Bartlett and his co-workers in the 1960s dramatically improved existing techniques and paved the way for long-term extracorporeal bypass 29 . Despite this, ECMO is not generally used unless conventional therapy has failed. Strict evaluation of patients is necessary as mortality correlates with age and comorbidity 14 . As such, ECMO is unlikely to be beneficial to those with irreversible lung disease, poor functional status or carcinomatosis.
There is always a risk of spontaneous haemorrhage due to the degree of anticoagulation required, though this may be reduced by the use of heparin-coated circuits or locally citrated circuits [30] [31] [32] . Despite adequate anticoagulation, clots may still form in the circuit and cause thromboembolic phenomena if they pass to the patient. For this reason veno-venous ECMO provides the systemic circulation with a degree of protection versus veno-arterial ECMO.
Oxygenators are prone to plasma leakage across the membrane resulting in a state analogous to pulmonary oedema. The incidence of this phenomenon has been reduced by the use of polymethylpentenecoated oxygenators that still allow good gas exchange performance while being almost entirely impermeable to liquid 33 . Other common complications include infection, damage to the cannulated vessel and surrounding structures 29, 34 and the possibility of adverse late vascular and neurological outcomes 35, 36 . ECMO is resource intensive and relatively expensive versus conventional critical care 37 . Due to cost restraints, ECMO is usually provided in supra-regional centres and as such many patients must be retrieved from other hospitals. Transport of the critically ill hypoxic patient is inherently risky although it is possible to take the equipment to the referring hospital and commence ECMO before transport 38 .
THE EVIDENCE SO FAR
As opposed to adults, there is good evidence of the benefits of ECMO for neonates. The United Kingdom Collaborative Randomized Trial of Neonatal Extracorporeal Membrane Oxygenation demonstrated a reduction in mortality at discharge from 59% with conventional management to 30% with ECMO 39 . It was a well constructed trial with experienced participating centres. However it is possible there was allocation bias due to the inevitable lack of treatment blinding and that infants on ECMO received a higher standard of care. The seven-year follow-up analysis found that ECMO, although being three times as expensive as conventional treatment, improved long-term survival from 41% to 67% and concluded it was cost-effective 40, 41 . These findings have been unanimously accepted by the neonatology community and ECMO has become standard care in some centres for severe respiratory failure due to meconium aspiration syndrome or persistent pulmonary hypertension of the newborn.
To clarify the existing evidence for ECMO on adult patients with ARDS, we performed a systematic literature review. An electronic search was conducted on MedLine (full database 1950 to present), EMBASE, the Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library and the Database of Abstracts of Reviews of Effects. Using the mapped subject terms "exp Extracorporeal Membrane Oxygenation/", "exp Extracorporeal Circulation/", "exp Respiratory Distress Syndrome, Adult/", "exp Respiratory Insufficiency/", "exp Adult/" and "exp Randomized Controlled Trials/", in isolation and combination, we identified 998 articles written in English. Our initial inclusion criterion was randomised, controlled trials assessing ECMO as a treatment measure against conventional treatment for patients with ARDS. When our search yielded only two such trials, published in 1979 and 1994 respectively, we felt it would be difficult to reach a robust conclusion on these alone. We therefore widened the search to include non-controlled trials, consistent with the principles outlined by the Metaanalysis of Observational Studies in Epidemiology group 42 . This revealed three non-randomised trials in which ECMO was used as a rescue therapy at the investigator's discretion. Inevitably non-controlled trials of ECMO will be subject to selection bias and, as such, the published data from these sources, while presented in this paper, has not been included in the statistical analysis. We have also referenced 35 relevant case series (n >1) for interest and further reading. The remaining papers comprising review articles, technical and apparatus reports, single patient case reports, or studies and case series in which acute respiratory failure was not the primary pathology requiring initiation of ECMO were excluded. Published mortality and patient demographic data for the five trials is presented for comparison in Tables 1  and 2 respectively.
The first formal study of ECMO in adults was commissioned by the National Institutes of Health 15 . It was a multi-centre randomised controlled trial conducted on 90 patients with acute respiratory failure comparing ECMO with conventional ventilation. Unfortunately survival to discharge was poor in both groups (<10%) with no statistically significant improvement in outcome. The rate of complications was not discussed in detail. However the authors postulated that decreased pulmonary blood flow due to the veno-arterial mode used may have contributed to the high incidence of pulmonary fibrosis. This trial was problematic in a number of ways. First, the trialists used the same ventilation mode in both arms, with unrestricted peak airway pressures thus negating the putative benefits of using circulatory support to avoid barotrauma 14 . Second, if patients failed to show clinical improvement after five days, ECMO was withdrawn, so the possibility of late improvement was not observed. Third, patients were enrolled with long pre-trial ventilation periods. It has since been demonstrated that there is a correlation between mortality and the number of ventilator days before commencing ECMO 43 . Fourth, there was a high incidence of bleeding on ECMO (average 2.5 l/day) probably due to excessive anticoagulation. Finally, to compound matters, many of the participating centres had little experience of ECMO before commencing the trial. In the light of the adverse outcome, interest in ECMO all but disappeared.
A second attempt to prove a favourable outcome was undertaken by Morris and colleagues in Utah 44 . In a single-centre randomised controlled trial the investigators enrolled patients with ARDS. They 15 n/a n/a 9.6 vs. 7.0 (0.05) n/a n/a n/a n/a n/a n/a compared extracorporeal carbon dioxide removal (ECCO 2 R) with pressure controlled inverse ratio ventilation, following on from a promising pilot study by Gattinoni 45 . Again, findings were not in favour of ECMO and the trial was stopped early after recruitment of 40 patients. The investigators had intended to enrol 60 patients over three years, but a β-projection on the two-year mortality data showed that a significant improvement in outcome was unlikely if they completed the trial. Their protocol differed from usual practice as they used a lower flow rate ECCO 2 R technique rather than full flow rate ECMO. Although one of their team was a collaborator from Gattinoni's study, the investigating unit only had experience of two adult ECMO cases (with one survivor) before starting the trial. They also experienced 21 episodes of non-CNS haemorrhage in the ECCO 2 R arm, seven of which necessitated ceasing that therapy. These factors in combination with the small patient numbers may explain why there was no significant improvement in outcome. Despite the poor results for ECMO, the trial did highlight the efficacy of inverse-ratio ventilation, paving the way for work by the ARDS Clinical Trials Network 46 . The two randomised trials were combined using the Bayesian random-effects model described by Warn 47 to obtain an overall estimate of the odds of mortality. Bayesian models are useful since they incorporate the heterogeneity between trials into the individual and overall estimates and allow probability statements to be made about quantities of interest. A prior distribution uniform on the interval 0 to 2 was placed on the between-studies standard deviation, as this was deemed to reflect a plausible degree of variability between the studies. A non-informative normal distribution with mean 0 and variance 10 was placed on the log-odds parameter. In this analysis interest is also in estimating the probability that the odds ratio is at least one. A probability of 50% implies a null effect whereas a probability above 90% implies evidence of harm and below 10% evidence of benefit. Figure 1 shows a forest plot of the pooled estimate from these two trials, in the odds ratio metric, using the Bayesian random-effects method. Results indicate no substantial evidence of benefit or harm (OR 1.28, 95% credible interval (CI) 0.24 to 6.55, P(OR>1)=64.0%). Changing the prior for the overall OR made no practical difference; however specifying the prior for the standard deviation between the studies to be uniform on a wider interval resulted in wider CIs although the point estimate for the variance remained quite stable.
The remaining trial data is from non-randomised sources. In a prospective cohort analysis conducted in Freiburg between 1991 and 1999, Mols and coworkers reported a 55% survival in ECMO and 61% in non-ECMO patients 30 . Lewandowski et al assessed a cohort of 122 relatively young patients with only moderate severity of illness in a noncontrolled prospective trial 34 . ECMO was used as rescue therapy and the survival differences, 55% in the ECMO and 89% in the non-ECMO groups, were perhaps not surprising. Both these studies confirmed an increment of mortality with prolonged ventilation before commencing ECMO 43 . Most recently Beiderlinden et al reported a prospective observational study of 150 patients with mean age 41.8 years and SAPS II score of 45, of whom 32 received extracorporeal support as rescue therapy 48 . In keeping with the previous two uncontrolled trials, the ECMO arm had worse physiological parameters than the conventional treatment group and this translated into a poorer outcome in the ECMO patients (survival: 53.1% vs. 71.2%). Their logistic regression analysis suggested that ECMO per se was not associated with mortality, thereby providing useful safety data. For all of these studies, patient age was low and severity of illness was modest. Furthermore, admission status differed between the groups and the selection criteria for institution of ECMO precluded any pooled quantitative analysis incorporating these data, in the absence of individual patient data. Many case series have been reported over the past 20 years. The largest was the cumulative report by the University of Michigan team of 255 adults treated between 1989 and 2004 49 . This represents one of the largest single centre experiences of ECMO in patients with ARDS. They reported a survival to discharge in 52% of patients and commented on the many changes to clinical practice over the data collection timeline. This and the other series are listed in Appendix 1.
ARDS is a complex and active disease process and there have been many developments in treatment in recent years. This is reflected in the dramatic improvement in mortality, especially in the conventional treatment arms, from Zapol in the 1970s and Morris in the early 1990s, when compared with the later trials 15, 44 . These randomised trials were regimented by ventilator protocols decided in advance, and without the hindsight of evidence on avoiding barotrauma and volutrauma. The nonrandomised trial investigators, by comparison, were at liberty to follow current trends and evidence and so alter their management accordingly to improve outcomes 30, 34, 48 .
WHAT TO LOOK OUT FOR
The CESAR trial should provide an authoritative answer as to the efficacy of ECMO in the adult patient population 4 . It is a single-centre, randomised controlled trial based at Glenfield Hospital, Leicester with patients recruited both locally and from distal units throughout the United Kingdom. Started in 2001, patients were enrolled with severe, but potentially reversible, respiratory failure. They reached their target of 180 patients in August last year and publication is expected later this year. The investigators will be analysing data on an intentionto-treat basis, hoping to demonstrate a reduction in mortality from 70% in the control arm down to 53% with ECMO. The high anticipated mortality rate expected in the control group is due to selection of patients with a Murray score of 3 or greater. Primary outcome measures are mortality and functional status at six months. Secondary outcomes include number of ventilator days, number of intensive care unit days, use of nitric oxide and prone positioning. There will also be analysis of economic and resource implications.
Australian intensivists may already be aware that a team at the Alfred Hospital in Melbourne are undertaking an audit of current practice across Australia and New Zealand 50 . This will be conducted in two stages. The first is to identify which centres offer ECMO and the second will be a prospective collection of patient and outcome data. Their stated aim is to develop guidelines and appropriate training programs for staff. The publication date has not yet been announced.
ALTERNATIVES TO ECMO
Opinion on the technology is divided. Centres such as the University of Michigan and Glenfield seem convinced that ECMO is effective in its current form, whereas others including Berlin and Galveston, Texas are working on alternative designs.
Rather than taking blood out of the body for oxygenation, Mortensen proposed implantation of an intravascular oxygenation system 51 . Phase I trials were disappointing and a randomised controlled trial failed to demonstrate a significant benefit 52, 53 . This may be due to gas exchange limitations with the available technology not facilitating a reduction in ventilation requirements despite use of a membrane oxygenator in later designs 54 . A modification of this technique utilising an intravascular pump to assist blood mixing and hence gas exchange may prove beneficial 55 .
Initial work on a pumpless arterio-venous circuit has led to development of the interventional lung assist. This has shown to be efficacious with the significant advantages over ECMO of lower running costs and less intensive nursing input needed, although the potential for gas exchange is reduced by passing already partially oxygenated arterial blood through the oxygenator. A retrospective analysis reported a mortality rate of 59% in patients with severe ARDS 56 . Not surprisingly, the survivors were younger and had less pre-existing co-morbidity. Unfortunately they experienced a 25% incidence of complications, mostly lower limb ischaemia. The investigators have also published a case series demonstrating the value of this technique to support critically ill patients during transport 57 .
Another desirable modification of the ECMO circuit would be to reduce its volume, lessening the surface area of foreign material exposed to blood and making operation easier. A successful mini-ECMO model has been recently described 58 . Further refinement of the system may permit a portable system affording patients better quality of life while awaiting lung and/or heart transplantation 59 . The drive to create a low-volume, pump-independent circuit has led to the development of the paracorporeal artificial lung 60 . This relies on the right ventricle to pump blood through an ultra-low resistance oxygenator placed either in series or parallel to the lungs 61 .
These alternatives are still in developmental stages and, to date, none has proved itself to be significantly beneficial, with a low rate of complications, while still remaining cost effective.
THE FUTURE FOR ECMO
As discussed in the introduction, despite lack of validation, ECMO has found a role in the treatment of adult patients with ARDS who fail to respond to conventional therapy. However in recent years the intensive care community has made great strides forward in our understanding of the pathophysiology of this condition. Since the proposal and commencement of the CESAR trial there have been a number of papers influencing our management of ARDS. Glenfield Hospital is the only ECMO centre in the U.K. offering a full-time adult service; yet it has taken them five years to recruit 180 patients. This suggests that advances in our understanding of ARDS may have resulted in a diminishing demand for this service and brings into question the need for a multicentre rollout.
Currently ECMO is offered by a small number of tertiary facilities and used as a rescue measure after conventional therapy has failed. It is hoped that the CESAR trial will provide valuable data on clinical efficacy and cost-effectiveness for adult patients. However, unless the findings are significantly in favour of ECMO, it is unlikely it will achieve more widespread acceptance and earlier adoption in eligible patients. APPENDIX 1 ARDS (9), lung graft failure (21) or other (3) 61% (off ECMO) 39% (to discharge)
